5/29
09:24 am
vrna
Verona prepares for anticipated US launch of ensifentrine for COPD in Q3 2024 [Yahoo! Finance]
Low
Report
Verona prepares for anticipated US launch of ensifentrine for COPD in Q3 2024 [Yahoo! Finance]
5/13
11:22 am
vrna
Verona Pharma plc (NASDAQ: VRNA) had its price target lowered by analysts at HC Wainwright from $33.00 to $30.00. They now have a "buy" rating on the stock.
Medium
Report
Verona Pharma plc (NASDAQ: VRNA) had its price target lowered by analysts at HC Wainwright from $33.00 to $30.00. They now have a "buy" rating on the stock.
5/10
12:18 pm
vrna
Verona Pharma plc (NASDAQ:VRNA) Q1 2024 Earnings Call Transcript [Yahoo! Finance]
Low
Report
Verona Pharma plc (NASDAQ:VRNA) Q1 2024 Earnings Call Transcript [Yahoo! Finance]
5/9
07:29 am
vrna
Verona Pharma Reports First Quarter 2024 Financial Results and Provides Corporate Update [Yahoo! Finance]
Medium
Report
Verona Pharma Reports First Quarter 2024 Financial Results and Provides Corporate Update [Yahoo! Finance]
5/9
07:15 am
vrna
Verona Pharma Reports First Quarter 2024 Financial Results and Provides Corporate Update
Low
Report
Verona Pharma Reports First Quarter 2024 Financial Results and Provides Corporate Update
5/9
07:06 am
vrna
Verona Pharma Announces $650 Million Strategic Financing with Oaktree and OMERS [Yahoo! Finance]
Low
Report
Verona Pharma Announces $650 Million Strategic Financing with Oaktree and OMERS [Yahoo! Finance]
5/9
07:00 am
vrna
Verona Pharma Announces $650 Million Strategic Financing with Oaktree and OMERS
Low
Report
Verona Pharma Announces $650 Million Strategic Financing with Oaktree and OMERS
5/2
02:10 am
vrna
Verona Pharma to Present Additional Analyses of Positive Phase 3 ENHANCE Studies in COPD at ATS 2024 [Yahoo! Finance]
Low
Report
Verona Pharma to Present Additional Analyses of Positive Phase 3 ENHANCE Studies in COPD at ATS 2024 [Yahoo! Finance]
5/2
02:00 am
vrna
Verona Pharma to Present Additional Analyses of Positive Phase 3 ENHANCE Studies in COPD at ATS 2024
Low
Report
Verona Pharma to Present Additional Analyses of Positive Phase 3 ENHANCE Studies in COPD at ATS 2024
4/25
02:00 am
vrna
Verona Pharma to Report First Quarter 2024 Financial Results and Provide Corporate Update
Low
Report
Verona Pharma to Report First Quarter 2024 Financial Results and Provide Corporate Update
4/16
10:10 am
vrna
Emphysema Treatment Market to Reach $8.7 Billion, Globally, by 2032 at 3.3% CAGR: Allied Market Research
Low
Report
Emphysema Treatment Market to Reach $8.7 Billion, Globally, by 2032 at 3.3% CAGR: Allied Market Research
4/16
10:10 am
vrna
Emphysema Treatment Market to Reach $8.7 Billion, Globally, by 2032 at 3.3% CAGR: Allied Market Research
Low
Report
Emphysema Treatment Market to Reach $8.7 Billion, Globally, by 2032 at 3.3% CAGR: Allied Market Research
4/16
08:00 am
vrna
Verona Pharma plc (NASDAQ: VRNA) had its price target raised by analysts at Piper Sandler from $31.00 to $36.00. They now have an "overweight" rating on the stock.
Low
Report
Verona Pharma plc (NASDAQ: VRNA) had its price target raised by analysts at Piper Sandler from $31.00 to $36.00. They now have an "overweight" rating on the stock.
3/4
08:06 am
vrna
Verona Pharma plc (NASDAQ: VRNA) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $32.00 price target on the stock.
Medium
Report
Verona Pharma plc (NASDAQ: VRNA) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $32.00 price target on the stock.
3/4
02:06 am
vrna
Andrew Fisher Joins Verona Pharma as General Counsel [Yahoo! Finance]
Medium
Report
Andrew Fisher Joins Verona Pharma as General Counsel [Yahoo! Finance]
3/4
02:00 am
vrna
Andrew Fisher Joins Verona Pharma as General Counsel
Medium
Report
Andrew Fisher Joins Verona Pharma as General Counsel